Clinical Trial Search

Primary: Effective Treatment Outcome (Direct Microscopy and Culture Negative and Total Signs and Symptom Score Less or Equal to 2) — 73; 10 participants

Primary: Percentage of Subjects With Complete Cure at Week 6. — 17.7; 7.1; 16.1; 3.1 percentage of subjects with complete cur — p=0.010

Primary: Primary Efficacy Endpoint: The Number of Patients in Each Treatment Group With a Therapeutic Cure of Tinea Pedis (Equivalence: Per-Protocol Population) — 89; 90…

Primary: Complete Cure of Interdigital Tinea Pedis — 16.8; 1.7 percentage of subjects — p=<0.025

Primary: Complete Cure of Interdigital Tinea Pedis — 26.0; 3.3 percentage of subjects — p=<0.025

Primary: Complete Cure — 63; 81; 19; 2 Participants

Primary: Naftifine Hydrochloride Pharmacokinetics Variables, Single and Multiple Dose — 138262.2; 15890.1; 68634.2; 17213.9 h*pg/mL

Primary: Safety Evaluation Cohort 1 — 8; 0; 0; 0 Feet

Primary: Proportion of Patients in Each Active Treatment Group Who Are Considered a Therapeutic Cure — 96; 81 Participants

Primary: Percentage of Subjects With Therapeutic Cure at 42 Days for All-analysis Population — 2; 1; 3; 0 Participants

Primary: Proportion of Subjects in Each Treatment Group With Therapeutic Success — 70; 95; 3 participants

Primary: Therapeutic Cure - Superiority Analysis — 76; 108; 24 Participants — p=0.0127

Primary: Number of Participants With Complete Cure: Post Treatment (Day 17) — 0; 4 Participants

Primary: Proportion of Subjects in Each Treatment Group With Therapeutic Success — 93; 88; 7 participants

Primary: Measurement of Circulating Plasma Levels of Luliconazole in Participants Who Had Tinea Pedis: Maximum Observed Plasma Concentration (Cmax) of Luliconazole — 3.27…

Primary: Percentage of Subjects — 25.3; 2.8 percentage of subjects with complete cur — p=0.025

Primary: Efficacy Assessed by Complete Cure Rate at the End of Study (Week 52) After Treating for 24 or 48 Weeks. — 0.79; 0.78; 1.47; 0.00 Percentage of Participants

Primary: Efficacy Assessed by the Percentage of Participants With Complete Cure at the End of Study (Week 52) After Treating for 24 or 48 Weeks — 1.50; 0.77; 2.96; 0 Percentage…

Primary: Complete Cure Rate: Interdigital Disease — 9; 9; 1 Participants

Primary: Nail Bed Clearing

Primary: Percentage of Participants With Complete Cure at the End of Study After Treating Participants for 48 Weeks — 1.18; 0.96 Percentage of participants

Primary: Treatment Related Adverse Events — 22; 8 Participants

Primary: Circulating Levels (Plasma Concentration) of Omeprazole Prior to Treatment With Luliconazole Cream 1% — 0; 0; 23.67; 196.30 ng/mL

Primary: The Effect of Ketoconazole 2% Foam for the Treatment of Tinea Versicolor — 7; 4 participants

Primary: Molecular Diagnostic qPCR Comparison of DBI-002 Drug Product and Malassezia (Fungal Cause of Tinea Versicolor) — 2; 4; 5; 1 Participants — p=0.2

Primary: Number of Participants With Local Tolerability Reactions by Severity — 54; 0; 1; 0 Participants

Primary: Circulating Plasma Concentration of Luliconazole at Day 7 (Pre-Dose) — 4.63; NA nanograms/milliliter (ng/mL)

Primary: Dermatophyte Species Distribution — 50; 37; 5; 12 isolates

Primary: Percentage of Participants With at Least One Adverse Event — 39 Participants

Primary: Primary Endpoint - Efficacy — 4 Participants